Blood pressure augmentation in acute ischemic stroke.
Although control of hypertension is established as an important factor in the primary and secondary prevention of stroke, management of blood pressure in the setting of acute ischemic stroke remains controversial. Given limited data, the general consensus is that there is no proven benefit to lowering blood pressure in the first hours to days after acute ischemic stroke. Instead, there is concern that relative hypotension may lead to worsening of cerebral ischemia. For many years, the use of blood pressure augmentation ("induced hypertension") has been studied in animal models and in humans as a means of maintaining or improving perfusion to ischemic brain tissue. This approach is now widely used in neurocritical care units to treat delayed neurological deficits after subarachnoid hemorrhage, but its use in ischemic stroke patients remains anecdotal. This article reviews the cerebral physiology, animal models and human studies of induced hypertension as a treatment for acute ischemic stroke. Although there has not been a large, randomized clinical trial of this treatment, the available clinical data suggests that induced hypertension can result in at least short-term neurological improvement, with an acceptable degree of safety.
Wityk
Robert J
RJ
Johns Hopkins University School of Medicine, Cerebrovascular Division, Johns Hopkins Hospital, Baltimore, MD 21287, USA. rwityk@jhmi.edu
D000208:Acute Disease; D000818:Animals; D001794:Blood Pressure / Q000502:physiology*; D002545:Brain Ischemia / Q000628:therapy*; D002560:Cerebrovascular Circulation; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000503:physiopathology; D010656:Phenylephrine / Q000627:therapeutic use; D020521:Stroke / Q000628:therapy*
D010656:Phenylephrine